New Insights into mTOR Signal Pathways in Ovarian-Related Diseases : Polycystic Ovary Syndrome and Ovarian Cancer
Creative Commons Attribution License.
mTOR, the mammalian target of rapamycin, is a conserved serine/threonine kinase which belongs to thephosphatidyl-linositol kinase-related kinase (PIKK) family. It has two complexes called mTORC1 and mTORC2. Itis well established that mTOR plays important roles in cell growth, proliferation and differentiation. Over-activationof the mTOR pathway is considered to have a relationship with the development of many types of diseases, includingpolycystic ovary syndrome (PCOS) and ovarian cancer (OC). mTOR pathway inhibitors, such as rapamycin and itsderivatives, can directly or indirectly treat or relieve the symptoms of patients suffering from PCOS or OC. Moreover,mTOR inhibitors in combination with other chemical-molecular agents may have extraordinary efficacy. This paperwill discuss links between mTOR signaling and PCOS and OC, and explore the mechanisms of mTOR inhibitors intreating these two diseases, with conclusions regarding the most effective therapeutic approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Asian Pacific journal of cancer prevention : APJCP - 17(2016), 12 vom: 01. Dez., Seite 5087-5094 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Ai Ling [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic Citation Status Publisher |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM268335443 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268335443 | ||
| 003 | DE-627 | ||
| 005 | 20231224222452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0894.xml |
| 035 | |a (DE-627)NLM268335443 | ||
| 035 | |a (NLM)28122439 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Ai Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New Insights into mTOR Signal Pathways in Ovarian-Related Diseases |b Polycystic Ovary Syndrome and Ovarian Cancer |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Creative Commons Attribution License | ||
| 520 | |a mTOR, the mammalian target of rapamycin, is a conserved serine/threonine kinase which belongs to thephosphatidyl-linositol kinase-related kinase (PIKK) family. It has two complexes called mTORC1 and mTORC2. Itis well established that mTOR plays important roles in cell growth, proliferation and differentiation. Over-activationof the mTOR pathway is considered to have a relationship with the development of many types of diseases, includingpolycystic ovary syndrome (PCOS) and ovarian cancer (OC). mTOR pathway inhibitors, such as rapamycin and itsderivatives, can directly or indirectly treat or relieve the symptoms of patients suffering from PCOS or OC. Moreover,mTOR inhibitors in combination with other chemical-molecular agents may have extraordinary efficacy. This paperwill discuss links between mTOR signaling and PCOS and OC, and explore the mechanisms of mTOR inhibitors intreating these two diseases, with conclusions regarding the most effective therapeutic approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a mTOR signaling pathway | |
| 650 | 4 | |a PCOS | |
| 650 | 4 | |a ovarian cancer | |
| 700 | 1 | |a Liao, Hong Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Cui Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Zi Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hong Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Cui Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Asian Pacific journal of cancer prevention : APJCP |d 2000 |g 17(2016), 12 vom: 01. Dez., Seite 5087-5094 |w (DE-627)NLM124868932 |x 2476-762X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:12 |g day:01 |g month:12 |g pages:5087-5094 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2016 |e 12 |b 01 |c 12 |h 5087-5094 | ||